Theratope therapeutic vaccine targeted to the STn epitope data

BIOMF (Edmonton, Alberta) reported interim Phase II data showing as good or better survival with Theratope as with traditional chemotherapy, without the toxicity of standard treatment.

As presented at the New Advances in Vaccine Technologies and Applications conference in Bethesda, Md., more than 50 percent of patients in the breast and ovarian groups are still alive. Compared to historical data, this gives similar survival as with a variety of chemotherapies. Data on 40 patients in the colorectal group show median survival of 14.4 months, also equivalent to historical data from chemotherapy. ...